Jill Sanchez - Mar 20, 2024 Form 4 Insider Report for VACCINEX, INC. (VCNX)

Role
Chief Financial Officer
Signature
/s/ Maurice Zauderer, Attorney-in-Fact for Jill Sanchez
Stock symbol
VCNX
Transactions as of
Mar 20, 2024
Transactions value $
$0
Form type
4
Date filed
3/22/2024, 04:31 PM
Previous filing
Mar 14, 2024
Next filing
May 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCNX Stock Option (Right to Buy) Award $0 +805 $0.00 805 Mar 20, 2024 Common Stock 805 $8.32 Direct F6
holding VCNX Stock Option (Right to Buy) 9 Mar 20, 2024 Common Stock 9 $1,045.80 Direct F1
holding VCNX Stock Option (Right to Buy) 9 Mar 20, 2024 Common Stock 9 $1,205.40 Direct F1
holding VCNX Stock Option (Right to Buy) 19 Mar 20, 2024 Common Stock 19 $802.20 Direct F2
holding VCNX Stock Option (Right to Buy) 19 Mar 20, 2024 Common Stock 19 $615.30 Direct F3
holding VCNX Stock Option (Right to Buy) 38 Mar 20, 2024 Common Stock 38 $270.90 Direct F4
holding VCNX Stock Option (Right to Buy) 76 Mar 20, 2024 Common Stock 76 $83.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully exercisable as of the date of this report.
F2 This option vests one-fourth on each of the first four anniversaries of the April 3, 2020 grant date, except as otherwise provided in the award notice.
F3 This option vests one-fourth on each of the first four anniversaries of the April 2, 2021 grant date, except as otherwise provided in the award notice.
F4 This option vests one-fourth on each of the first four anniversaries of the April 1, 2022 grant date, except as otherwise provided in the award notice.
F5 This option vests one-fourth on each of the first four anniversaries of the March 31, 2023 grant date, except as otherwise provided in the award notice.
F6 This option was granted under the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests one-fourth on each of the first four anniversaries of the March 30, 2024 grant date.